Kiora Pharmaceuticals, Inc. (KPRX) fundamentals score
Kiora Pharmaceuticals is developing KIO-301, with an initial focus on patients with later stages of vision loss due to retinitis pigmentosa (collectively including any and all sub-forms, "RP"). KIO-301 is a potential vision-restoring small molecule that acts as a “photoswitch” specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including RP.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 2.9 out of 10, Unhealthy fundamentals
- Growth: 2.3/10
- Profitability: 1.0/10
- Financial health: 5.5/10
- Earnings quality: 5.2/10
- Valuation: 1.5/10
Scores are calculated from Kiora Pharmaceuticals, Inc.’s SEC filings, using the 12 months through 2025-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10